ProActive Capital Resources Group has received compensation from FluoroPharma to provide research and investor relations coverage for a period of time.
FluoroPharma Medical, Inc. (OTCQB: FPMI) engages in the discovery, development and commercialization of proprietary medical diagnostic imaging products. The company's initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (NYSEARCA:CAD). Below is a summary of the Company's pipeline:
1.) BFPET is being evaluated in an on going investigator-sponsored Phase 1 clinical trial in China for imaging agent to measure cardiovascular blood flow with expected conclusion of the 20-patient study during 4Q12 to support start of planned Phase 2 trials. In late July, $FPMI announced high quality images were obtained in the study conducted by Dr. Alan Fischman, who is the former head of nuclear medicine at Massachusetts General Hospital.
Dr. Fischman had a positive commentary on the results and potential of BFPET, stating, "Initial results are impressive. Image quality obtained using PET is superb. BFPET shows clear diagnostic qualities as well as increased resolution, inherent in PET. The initial images look spectacular and we are confident that when all the patients are imaged, the data will further support clinical development of the agent."
2.) CardioPET is currently being evaluated in an open-label Phase 2 study as a diagnostic imaging agent to assess perfusion of the heart and fatty acid uptake in heart muscle in patients that have coronary artery disease. The study is being conducted at two sites in Belgium with results expected later this year.
3.) VasoPET is being developed as a diagnostic imaging agent that accumulates in areas of inflammation, making it useful for the identification of patients that have experienced a heart attack or stroke that are at risk for a potential recurrence with a Phase 1 clinical trial expected to begin early next year.
4.) AZPET is a development-stage imaging agent that attaches to brain a myloid plaques making them visible on a PET scan to allow for the early detection of Alzheimer's disease.
With cardiovascular disease representing the leading cause of death worldwide, $FPMI is well positioned as an emerging diagnostic company in the space with several promising imaging agents with the potential to improve patient outcomes through more precise and targeted imaging results. In addition, the Company has an earlier stage asset for the early detection of Alzheimer's disease, which is in dire need of better diagnostic tests and treatments to slow or halt progression through early intervention and more effective treatments.